AXSM AXSOME THERAPEUTICS INC. revenue, earnings and financials
For the quarter ended June 30, 2026, AXSOME THERAPEUTICS INC. reported revenue of $218M (up 45.5% from a year earlier), net income of −$51.3M and diluted EPS of −$0.99; over the last four quarters revenue was $777M and net income −$192M; for the fiscal year ended December 2025 revenue was $638M, up 65.5% on the year before.
AXSM annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $638M, gross profit n/a, operating income −$167M, net income −$183M (margin -28.7%), EPS −$3.68
- Fiscal year ended Dec 2024: revenue $386M, gross profit n/a, operating income −$281M, net income −$287M (margin -74.5%), EPS −$5.99
- Fiscal year ended Dec 2023: revenue $271M, gross profit n/a, operating income −$232M, net income −$239M (margin -88.4%), EPS −$5.27
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$180M, net income −$187M (margin n/a), EPS −$4.60
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$125M, net income −$130M (margin n/a), EPS −$3.47
AXSM quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $218M (up 45.5% year over year), net income −$51.3M, EPS −$0.99
- Quarter ended Mar 31, 2026: revenue $191M (up 57.4% year over year), net income −$64.5M, EPS −$1.26
- Quarter ended Dec 31, 2025 (from the annual report): revenue $196M (up 65.0% year over year), net income −$28.6M, EPS −$0.55
- Quarter ended Sep 30, 2025: revenue $171M (up 63.2% year over year), net income −$47.2M, EPS −$0.94
- Quarter ended Jun 30, 2025: revenue $150M (up 72.1% year over year), net income −$48.0M, EPS −$0.97
- Quarter ended Mar 31, 2025: revenue $121M (up 62.0% year over year), net income −$59.4M, EPS −$1.22
- Quarter ended Dec 31, 2024 (from the annual report): revenue $119M (up 66.0% year over year), net income −$74.9M, EPS −$1.54
- Quarter ended Sep 30, 2024: revenue $105M (up 81.3% year over year), net income −$64.6M, EPS −$1.34
- Quarter ended Jun 30, 2024: revenue $87.2M (up 86.7% year over year), net income −$79.3M, EPS −$1.67
- Quarter ended Mar 31, 2024: revenue $75.0M (down 20.7% year over year), net income −$68.4M, EPS −$1.44
- Quarter ended Dec 31, 2023 (from the annual report): revenue $71.5M, net income −$98.7M, EPS −$2.15
- Quarter ended Sep 30, 2023: revenue $57.8M (up 243.1% year over year), net income −$62.2M, EPS −$1.32
- Quarter ended Jun 30, 2023: revenue $46.7M (up 429.5% year over year), net income −$67.2M, EPS −$1.54
- Quarter ended Mar 31, 2023: revenue $94.6M, net income −$11.2M, EPS −$0.26
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$61.2M, EPS −$1.41
- Quarter ended Sep 30, 2022: revenue $16.8M, net income −$44.8M, EPS −$1.07
- Quarter ended Jun 30, 2022: revenue $8.82M, net income −$41.4M, EPS −$1.06
- Quarter ended Mar 31, 2022: revenue n/a, net income −$39.6M, EPS −$1.06
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$34.0M, EPS −$0.90
- Quarter ended Sep 30, 2021: revenue $0, net income −$34.9M, EPS −$0.93
AXSM cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$93.4M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$128M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$145M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$117M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$108M, share buybacks n/a
AXSM balance sheet
- Jun 30, 2026: cash $320M, total assets $761M, total liabilities $678M, shareholders' equity $83.3M, long-term debt $118M
- Mar 31, 2026: cash $305M, total assets $714M, total liabilities $659M, shareholders' equity $54.6M, long-term debt $118M
- Dec 31, 2025: cash $323M, total assets $690M, total liabilities $602M, shareholders' equity $88.3M, long-term debt $118M
- Sep 30, 2025: cash $325M, total assets $669M, total liabilities $596M, shareholders' equity $73.7M, long-term debt $118M
- Jun 30, 2025: cash $303M, total assets $640M, total liabilities $567M, shareholders' equity $73.1M, long-term debt $118M
- Mar 31, 2025: cash $301M, total assets $597M, total liabilities $543M, shareholders' equity $53.2M, long-term debt $181M
- Dec 31, 2024: cash $315M, total assets $568M, total liabilities $511M, shareholders' equity $57.0M, long-term debt $181M
- Sep 30, 2024: cash $327M, total assets $561M, total liabilities $469M, shareholders' equity $92.9M, long-term debt $180M
What is AXSM's revenue?
AXSOME THERAPEUTICS INC. reported $777M of revenue over its last four quarters, through June 30, 2026.
Is AXSM profitable?
No. AXSOME THERAPEUTICS INC. lost $192M over the last four quarters.
What is AXSM's EPS?
Diluted earnings per share over the last four quarters were −$3.74; −$0.99 in the latest quarter.